Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

BIOSANTE Form 4 July 16, 2013	PHARMACEU'	FICALS I	NC							
FORM	ГЛ								PPROVAL	
	UNITED	STATES		RITIES A ashington			E COMMISSIO	N OMB Number:	3235-0287	
Check thi if no long	or			C				Expires:	January 31,	
subject to Section 1 Form 4 or	6. SIAIE N	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES						Estimated burden hor response	urs per	
Form 5 obligation may cont <i>See</i> Instru 1(b).	inue. Section 17	(a) of the l	Public U	Jtility Hol	ding Co		inge Act of 1934, t of 1935 or Secti 1940			
(Print or Type F	Responses)									
1. Name and Address of Reporting Person <u></u> MARSHBANKS TRACY			2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICA			-	5. Relationship of Reporting Person(s) to Issuer			
			INC [E		ind in ite		(Che	eck all applicabl	e)	
(Last)				3. Date of Earliest Transaction (Month/Day/Year)			X_ Director 10% Owner Officer (give title Other (specify below) below)			
1 SOUTH W DRIVE, SU			07/12/2	2013			below)	below)		
CHICAGO,	(Street) IL 60606			endment, D onth/Day/Yea	-	al	6. Individual or Applicable Line) _X_ Form filed by Form filed by Person		erson	
(City)	(State)	(Zip)	Tat	ole I - Non-J	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned	
	2. Transaction Date (Month/Day/Year)		ed Date, if	3. Transactic Code (Instr. 8)	4. Securi	ties (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
				Code V	Amount		(Instr. 3 and 4)			
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities bene	-	-	-			
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	• Beneficially Owner securities)	d		
1. Title of 2	. 3. Tran	saction Date	e 3A. De	emed	4.	5. Numbe	er of 6. Date Exerc	isable and	7. Title and Amo	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	Derivative	Expiration Date	Underlying Securities

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day	/Year)	(Instr. 3 and	4)
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase	\$ 1.06	07/12/2013		А	20,000	<u>(1)</u>	07/11/2023	Common Stock	20,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MARSHBANKS TRACY 1 SOUTH WACKER DRIVE SUITE 3900 CHICAGO, IL 60606	Х					
Signatures						

Tracy L.	
Marshbanks	07/16/2013
<u>**Signature of</u>	Date

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Option vests over a four year period beginning on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.